1. TECAM
Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear cell injection (BMMC; n = 30), vs. granulocyte-colony stimulating factor (G-CSF; n = 30), vs. BMMC + G-CSF (n = 29), vs. control (n = 31).
(p = 0.37 between groups)
Results
Change in left ventricular ejection fraction from baseline to follow-up: 6% in the BMMC group, vs. 2% in the G-CSF group, vs. 4% in the BMMC + G-CSF group, versus 4% in the control group (p = 0.37) 6 % 4 4 2
Conclusions
Among STEMI patients who underwent successful reperfusion with sirolimus-eluting stents, cell therapy was unable to improve left ventricular function at 1 year
Cell therapy consisted of intracoronary injection of BMMCs, mobilization with G-CSF, or combination of BMMCs and G-CSF
BMMC
G-CSF
BMMC + G-CSF
Control
San Roman JA, et al. J Am Coll Cardiol 2015;65: